The Female Health Company to Present at Sidoti's Semiannual New York Micro-Cap Conference

  //house-home.news-articles.net/content/2011/01/0 .. -s-semiannual-new-york-micro-cap-conference.html
  Published in House and Home on Tuesday, January 4th 2011 at 5:35 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

The Female Health Company to Present at Sidoti's Semiannual New York Micro-Cap Conference -- CHICAGO, Jan. 4, 2011 /PRNewswire/ --

CHICAGO, Jan. 4, 2011 /PRNewswire/ -- The Female Health Company (Nasdaq: FHCO),which manufactures and markets the FC2 Female Condom®, today announced that O.B. Parrish, CEO, and Donna Felch, CFO, are scheduled to make a presentation at the Sidoti Semiannual New York Micro-Cap Conference at 8:40 AM Eastern Time on Monday, January 10, 2011.  The Company's executives will also meet with investors to discuss the Company's ongoing operations.  The conference will be held at the Grand Hyatt New York Hotel in Midtown Manhattan.

About Sidoti & Company, LLC

Sidoti & Company, LLC Micro-Cap Conference is one of the largest micro-cap focused investor events in the U.S., with over 400 institutional investor attendees at the previous micro-cap conference.  For more information or to register for the conference, please contact Justin Ruiss by phone at (212) 453-7008 or via e-mail at [ jruiss@sidoti.com ].

Sidoti & Company, LLC, founded in 1999, continues to set the Wall Street standard for small-cap equity research.  Analysts mine dozens of industries to provide unbiased, institutional-quality research on more than 500 largely undiscovered, profitable companies at a market capitalization below $3 billion.  The firm, also, is quickly becoming the leading provider of research in the micro-cap arena.  Sidoti & Company, LLC, now covers more than 50 names in that sector.  The number is growing steadily.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and about 100 other countries around the world.  The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., Europe, China, Canada, Australia, South Africa, Japan, Spain, Greece and Turkey, and pending in various countries.  The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.  The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.  

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings.  Actual events affecting the Company and the impact of such events on the Company's operations may vary from this currently anticipated.

For more information about the Female Health Company visit the Company's website at [ http://www.femalehealth.com ] and [ http://www.femalecondom.org ]. If you would like to be added to the Company's e-mail alert list, please send an e-mail to [ FHCInvestor@femalehealthcompany.com ] .

SOURCE The Female Health Company

RELATED LINKS
[ http://www.femalehealth.com ]